Abstract
Abstract not available.
Highlights
Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies
● Janus kinases (JAKs) modulate inflammatory cytokines involved in the pathogenesis of AD3 and may directly modulate itch4
● The primary endpoint was the proportion of patients achieving Investigator’s Global Assessment (IGA)-treatment success (IGA-TS; score of 0/1 with ≥2-grade improvement from baseline) at Week 8
Summary
● Atopic dermatitis (AD) is a chronic, inflammatory skin disease that greatly impacts patients’ quality of life. ● Ruxolitinib (RUX) is a potent, selective inhibitor of JAK1 and JAK25 ● In a phase 2 study (NCT03011892), RUX cream provided strength-dependent efficacy in patients with AD and a safety profile similar to vehicle
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
